2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - Great Hall AD
Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Profiling, Biological Processes, Pathogenesis, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric
PAPER

387 Measurable residual disease after two chemotherapy cycles predicts relapse and survival in children with KMT2A-rearranged acute myeloid leukaemia: Results from the MyeChild01 trial

Carlos Jimenez-Vicente, MD, PhD, Jelena Jovanovic, PhD2, Hélène Lapillonne, MD, PhD3, Nicolas Duployez, MD4, Shanna Maycock, MSc5, Anna Lawson6, Aimee Jackson, MSc7, Philip Ancliff, FRCPath8, Andrew Scott Moore, MBBS, FRACP, PhD9, Owen Smith, MD10, Nicola Potter, PhD11, Manohursingh Runglall12, Phoebe Aucken, BSc13, William Villiers, PhD14, Geoff Shenton, MBChB, FRCPath, FRCPCH, MRCP15, Nicolas Heaney, MBChB, BSc, MD16, Marc Ansari, MD17, Christine Harrison, PhD, FMedSci18, Lucy Wheeler19, Boutheina Bouslama, PharmD20, Paola Ballerini, MD, PhD21, Christophe Roumier, MD22, Elise Fournier23, Guy Leverger24, André Baruchel, MD25, Andrew Wood, MBChB26, Claude Preudhomme, PhD27, Arnaud Petit, MD, PhD28, Brenda E.S. Gibson29, Richard Dillon, MBBS30
1 King's College London, London, United Kingdom
2 King's College London, London, United Kingdom
3 Sorbonne Université, APHP Hôpital Trousseau and INSERM UMR_S938, Paris, France
4 CHU Lille, Lille, France
5 University of Birmingham, Birmingham, United Kingdom
6 University of Birmingham, Birmingham, United Kingdom
7 University of Birmingham, Birmingham, United Kingdom
8 Great Ormond Street Hospital for Children, London, United Kingdom
9 Queensland Children's Hospital, Brisbane, Queensland, Australia
10 Children's Health Ireland at Crumlin, Dublin, Ireland
11 King's College London, London, United Kingdom
12 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, King's College London, London, United Kingdom
13 King's College London, London, United Kingdom
14 King's College London, London, United Kingdom
15 Great North Children’s Hospital, Newcastle Upon Tyne, United Kingdom
16 Royal Hospital for Children, Glasgow, United Kingdom
17 Geneva University Hospital, Geneva, Switzerland
18 Newcastle University, Newcastle-upon-Tyne, United Kingdom
19 Southmead Hospital, Bristol, United Kingdom
20 Sorbonne Université, APHP Hôpital Trousseau, Paris, France
21 APHP-Sorbonne Universite, Paris, France
22 CHU Lille, Lille, France
23 CHU Lille, Lille, France
24 Hopital Armand Trousseau, Paris, France
25 Robert Debré University Hospital APHP, Paris, France, Université Paris Diderot, Paris, France
26 Starship Children's Health, Auckland, New Zealand
27 CHU LILLE, Lille, France
28 Sorbonne Universite, Paris, France
29 Royal Hospital for Children, Glasgow, United Kingdom
30 King's College London, London, United Kingdom

Background

For children with KMT2A rearranged (KMT2Ar) acute myeloid leukemia (AML) the prognostic value, clinical utility and optimal technique for measurable residual disease (MRD) assessment remain poorly defined.

Integrating MRD with baseline genetic risk could identify children at low risk of relapse who are likely to be cured with chemotherapy alone, those at higher risk of relapse who may be directed to transplant and those likely to have poor outcomes despite transplant for whom novel therapies may be considered: this is important for the development of risk adapted treatment protocols.

Here we present the outcomes of 175 children with KMT2Ar AML in the MyeChild01 study according to their MRD status and compared the performance of different MRD techniques.

 

Methods

MyeChild01 enrolled 748 children with newly diagnosed AML across six countries between June 2016 and March 2025. MRD was assessed prospectively after each course of treatment and before transplant using multicolour flow cytometry (MFC) and molecular methods in parallel in central laboratories. If there was a discrepancy, MFC results took precedence for treatment decisions. Molecular MRD was measured using RT-qPCR, RT-dPCR or genomic DNA qPCR (together, PCR-MRD).

Children with KMT2A::AFDN, AFF1 or MLLT10 were designated high-risk (HR), as were those with refractory disease after course 1 (C1). They received FLA-Ida for course 2 (C2) and were recommended for an allogeneic transplant (alloSCT) in 1st complete remission (CR1). Children with intermediate-risk (IR) genetics who failed to achieve a 3-log reduction in MRD after C2 also became HR. Other children were treated with consolidation chemotherapy only.

We performed a post-hoc analysis of overall survival (OS) and relapse-free survival (RFS) according to MRD status. We also compared the technical performance of different molecular MRD assays by analysing 39 samples using all three molecular assays.

 

Results

KMT2A fusion partner classified 101 (58%) as intermediate and 73 (42%) as high-risk. Three-year OS and RFS were 73% and 58%. There were no differences in OS or RFS between these groups.

After C1, 13/129 (10%) were MRD positive by MFC and 19/153 (12%) by PCR; neither were prognostic for either OS or RFS at any examined threshold, or when restricting the analysis to HR or IR cytogenetics.

After C2, 8/118 (6.8%) were MRD positive by MFC and 19/145 (13%) by PCR. At this timepoint, MRD status was clearly predictive of outcome for both techniques: MFC 3y OS 78% vs 38% HR 4.4 (95% CI 1.7–11.6, p=0.001), 3y RFS 63% vs 38% HR 2.9 (1.1–7.3, p=0.02); PCR 3y OS 78% vs 50% HR 2.8 (1.3–5.9, p=0.005), RFS 61% vs 39% HR 2.5 (1.3–4.8, p=0.003).

Seven children (6 with IR cytogenetics) were MFC- but PCR+ after C2. They had increased relapse compared to double-negative patients (3y RFS 43% vs 64%) but similar OS (3y 71% vs 80%).

For children with IR cytogenetics, 66/68 (97%) and 78/91 (86%) tested MRD negative by FCM and PCR respectively after C2, and did not receive CR1 alloSCT. Their 3y OS was 80% (FCM-) and 77% (PCR-), and RFS was 64% and 60%.

For those with HR cytogenetics, 6/49 (12%) tested MRD+ by FCM and 6/54 (11%) by PCR after C2, 3y OS and RFS were both 33% (FCM+) and 17% (PCR+).

63/175 (36%) underwent allo-SCT in CR1 of whom 53 (84%) had HR cytogenetics. A further 12 underwent allo-SCT after relapse. Before transplant, 6/58 (10%) were MRD positive by MFC and 14/69 (20%) by molecular methods; both were predictive: MFC 3y OS 77% vs 33% HR 3.5 (1.2–11); PCR 3y OS 78% vs 40% HR 3.4 (1.5–8.1).

RT-qPCR and RT-dPCR results showed qualitative concordance in 37/38 (97%) evaluable samples. There was also a strong quantitative correlation for positive samples (r=0.827, p<0.001). Preliminary comparisons with DNA-based qPCR show similar trends.

 

Conclusions

In this risk-adapted protocol, outcomes for children with IR and HR KMT2A fusions were similar, suggesting that intensified chemotherapy and CR1-alloSCT can offset adverse baseline genetic risk.

Detection of MRD after C2 identifies a small group of children with adverse outcomes in both the IR and HR groups. In the IR group, the increased risk of relapse warrants consideration of CR1-alloSCT. In the HR group poor outcomes for MRD-positive patients even after transplant supports the prospective evaluation of menin inhibitors or other novel therapies.

Different molecular methods were strongly concordant and identified approximately twice as many high-risk children as flow cytometry.

Carlos Jimenez-Vicente, MD, PhD: No relevant conflicts of interest to declare.